Recombinant Rat Endoglin/CD105 Fc Chimera Protein, CF
Recombinant Rat Endoglin/CD105 Fc Chimera Protein, CF Summary
Product Specifications
| Rat Endoglin (Met1-Gly578) Accession # NP_001010968 |
IEGRMDP | Mouse IgG2A (Glu98-Lys330) |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
6440-EN
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
6440-EN
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 250 μg/mL in PBS. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: Endoglin/CD105
Endoglin (CD105) is a 90 kDa type I transmembrane glycoprotein of the zona pellucida (ZP) family of proteins (1‑3). Endoglin and betaglycan/T beta RIII are type III receptors for TGF-beta superfamily ligands, sharing 71% aa identity with the transmembrane (TM) and cytoplasmic domains. Endoglin is highly expressed on proliferating vascular endothelial cells, chondrocytes, and syncytiotrophoblasts of term placenta, with lower amounts on hematopoietic, mesenchymal and neural crest stem cells, activated monocytes, and lymphoid and myeloid leukemic cells (2‑5). Rat Endoglin cDNA encodes 650 amino acids (aa) including a 25 aa signal sequence, a 553 aa extracellular domain (ECD) with an orphan domain and a two-part ZP domain, a TM domain and a 51 aa cytoplasmic domain (1‑3). In human and mouse, an isoform with a 14 aa cytoplasmic domain (S‑endoglin) can oppose effects of long (L) Endoglin (6). In rat, a potential isoform with a 100 aa cytoplasmic tail (49 aa inserted after aa 610) diverges at the same aa as S‑endoglin (7). The rat Endoglin ECD shares 84%, 70%, 68%, 64%, and 62% aa identity with mouse, human, canine, porcine, and bovine Endoglin, respectively. Endoglin homodimers interact with TGF-beta 1 and TGF-beta 3 (but not TGF-beta 2), but only after binding T beta RII (8). Similarly, they interact with activin-A and BMP-7 via activin type IIA or B receptors, and with BMP-2 via BMPR-1A/ALK-3 or BMPR-1B/ALK-6 (9). BMP-9, however, is reported to bind Endoglin directly (10). Endoglin modifies ligand-induced signaling in multiple ways. For example, expression of Endoglin can inhibit TGF-beta 1 signals but enhance BMP7 signals in the same myoblast cell line (11). In endothelial cells, Endoglin inhibits T beta RI/ALK-5, but enhances ALK‑1‑mediated activation (12). Deletion of mouse Endoglin causes lethal vascular and cardiovascular defects, and human Endoglin haploinsufficiency can cause the vascular disorder, hereditary hemorrhagic telangiectasia type I (13, 14). These abnormalities confirm the essential function of Endoglin in differentiation of smooth muscle, angiogenesis, and neovascularization (2‑4, 12‑14). In preeclampsia of pregnancy, high levels of proteolytically generated soluble Endoglin and VEGF R1 (sFLT1), along with low placental growth factor (PlGF), are pathogenic due to antiangiogenic activity (15).
- Gougos, A. and Letarte, M. (1990) J. Biol. Chem. 265:8361.
- ten Dijke, P. et al. (2008) Angiogenesis 11:79.
- Bernabeu, C. et al. (2007) J. Cell. Biochem. 102:1375.
- Mancini, M.L. et al. (2007) Dev. Biol. 308:520.
- Moody, J.L. et al. (2007) Stem Cells 25:2809.
- Velasco, S. et al. (2008) J. Cell Sci. 121:913.
- GenBank Accession # AA105861.
- Cheifetz, S, et al. (1992) J. Biol. Chem. 267:19027.
- Barbara, N.P. et al. (1999) J. Biol. Chem. 274:584.
- Scharpfenecker, M. et al. (2007) J. Cell Sci. 120:964.
- Scherner, O. et al. (2007) J. Biol. Chem. 282:13934.
- Pece-Barbara, N. et al. (2005) J. Biol. Chem. 280:27800.
- Arthur, H.M. et al. (2000) Dev. Biol. 217:42.
- Lebrin, F. and C.L. Mummery (2008) Trends Cardiovasc. Med. 18:25.
- Venkatesha, S. et al. (2006) Nat. Med. 12:642.
Citation for Recombinant Rat Endoglin/CD105 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Dysregulation of the Fas/FasL system in an experimental animal model of HELLP syndrome
Authors: J Gibbens, R Morris, T Bowles, SK Spencer, K Wallace
Pregnancy Hypertens, 2017-02-24;8(0):26-30.
Species: Rat
Sample Types: In Vivo
Applications: In Vivo
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Rat Endoglin/CD105 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Rat Endoglin/CD105 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Rat Endoglin/CD105 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
